Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.6 %

Shares of NYSE BTX opened at $1.81 on Thursday. The company has a 50 day simple moving average of $1.90 and a two-hundred day simple moving average of $1.97. The stock has a market cap of $106.48 million, a price-to-earnings ratio of -0.80 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.